Amarin’s Vazkepa gets green light from SMC
Treatment will help reduce the risk of heart attacks and strokes for patients across Scotland
Read More
Tag: Amarin
Amarin’s Vazkepa secures NICE recommendation
It is the first treatment in its class to receive NICE approval for cardiovascular risk reduction
Read More
MHRA authorises Amarin’s heart drug Vazkepa
Drug demonstrated a 25% relative risk reduction in the first occurrence of major adverse cardiovascular events in REDUCE-IT trial
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
